Algorae Pharmaceuticals Limited
LVCLF
$0.0063
$0.000916.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | 195.00% | 186.11% | -- |
| Total Revenue | -- | -- | 195.00% | 186.11% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 195.00% | 186.11% | -- |
| SG&A Expenses | -86.28% | -85.95% | 3.68% | 0.97% | 69,125.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -66.82% | -66.03% | -7.20% | -9.46% | 33.66% |
| Operating Income | 66.82% | 66.03% | 22.59% | 24.48% | -33.66% |
| Income Before Tax | 55.01% | 53.97% | 20.67% | 22.61% | -10.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.01% | 53.97% | 20.67% | 22.61% | -10.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.01% | 53.97% | 20.67% | 22.61% | -10.06% |
| EBIT | 66.82% | 66.03% | 22.59% | 24.48% | -33.66% |
| EBITDA | -- | -- | 22.60% | 24.49% | -33.67% |
| EPS Basic | 66.67% | 66.67% | 50.00% | 50.00% | 0.00% |
| Normalized Basic EPS | 50.00% | 50.00% | 0.00% | 0.00% | 0.00% |
| EPS Diluted | 66.67% | 66.67% | 50.00% | 50.00% | 0.00% |
| Normalized Diluted EPS | 50.00% | 50.00% | 0.00% | 0.00% | 0.00% |
| Average Basic Shares Outstanding | 2.90% | 2.90% | 19.72% | 19.72% | 27.57% |
| Average Diluted Shares Outstanding | 2.90% | 2.90% | 19.72% | 19.72% | 27.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |